Cryo-Cell International

Name

Cryo-Cell International

Legal name

Cryo-Cell International, Inc.

Website

https://cryo-cell.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

51–100 employees

Short description

Cryo-Cell International is the world's first private cord blood bank, founded in 1989, offering cryopreservation of umbilical cord blood and cord tissue stem cells for over 500,000 parents across 87 countries. Revenue is generated primarily through subscription-based processing and annual storage fees, with auxiliary biotech R&D through Duke University and USF partnerships.

Ownership category

akta.pro rank

Product category

Stem Cell Banking Services

NAICS

Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industries

Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ), Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG), Blood, Organ & Tissue Donation Organizations (BPAGACAJ)

Keywords

• Private cord blood banking
• Cord tissue cryopreservation
• Newborn stem cell storage
• Menstrual stem cell service
• Regenerative medicine banking

Headquarters

HQ city

Oldsmar

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Operations, Personnel, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

1. Processing and Storage Fees: Cryo-Cell charges expectant parents one-time processing fees and recurring annual storage fees for the cryopreservation of cord blood and cord tissue stem cells. Revenue from processing and storage fees constituted $31.4 million of the company's $31.6 million in consolidated fiscal 2025 revenue.
2. Public Banking Revenue: Revenue generated from public cord blood banking services, representing $130,000 of consolidated fiscal 2025 revenue.
3. Product Revenue: Revenue from product sales related to cord blood and cord tissue banking services, representing $54,000 of consolidated fiscal 2025 revenue.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Cryo-Cell International provides private cord blood and cord tissue banking services, collecting, processing, and cryopreserving newborn umbilical cord blood and tissue stem cells for family use. The company also offers the CéElle menstrual stem cell service and bundled plans (U-Cord Plus, P3 Protect). Revenue is generated primarily from one-time processing fees and recurring annual storage fees for cryogenic preservation in cGMP/cGTP-compliant facilities.

Product overview

Cryo-Cell International operates as a private cord blood bank offering a portfolio of stem cell preservation services. The core offerings include Cord Blood Banking and Cord Tissue Banking, which can be purchased separately or combined through U-Cord Plus. The company also provides Célle, the world's first menstrual stem cell banking service, and the P3 Protect Baby, Protect Mom, Protect Family plan that bundles multiple services. Supporting products include PrepaCyte-CB premium processing technology, the Advanced Collection Kit with enhanced temperature protection, and the 5-Chamber Cord Blood Cryo-Bag for multi-use storage. Educational services such as webinars and a video center support customer onboarding.

Differentiator

Problem solved

Functional benefit

Brands

• Célle: World's first commercial service allowing women to cryopreserve their own menstrual stem cells, launched November 2007
• U-Cord Plus
• P3 Protect Baby, Protect Mom, Protect Family

Products and services

• Cord Blood Banking Primary service collecting, processing, and cryopreserving umbilical cord blood stem cells for private family banking. Marketed to expectant parents for potential future therapeutic use against 80+ FDA-approved conditions.
• Cord Tissue Banking Service for cryopreserving umbilical cord tissue, a rich source of mesenchymal stem cells (MSCs) used in regenerative medicine research for conditions including heart disease, stroke, multiple sclerosis, and diabetes.
• CéElle Menstrual Stem Cell Service World's first commercial service allowing women to cryopreserve their own menstrual stem cells, which can differentiate into many cell types including cardiac and neural cells.
• U-Cord Plus Advanced bundled service combining Cryo-Cell's signature U-Cord cord blood product with cord tissue storage, providing families with multiple stem cell preservation options from a single birth.
• P3 Protect Baby, Protect Mom, Protect Family Exclusive family healthcare protection plan combining U-Cord Plus (cord blood plus cord tissue) with the CéElle menstrual stem cell service, designed to extend healthcare protection across the family.

Quantifiable outcome

• 100% of client collections have been successfully viable upon thaw since inception
• +3 more outcomes

Named customers8 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• University of South Florida (USF)coreStrategic or Co-development Partner · 8 March 2011Cryo-Cell collaborates with USF's Department of Neurosurgery and Brain Repair on research into the therapeutic potential of cord blood stem cells for neurodegenerative diseases including stroke, Alzheimer's disease, and ALS. Research is conducted through Saneron CCEL Therapeutics, a Cryo-Cell affiliate. Dr. Paul Sanberg and Dr. Cesar Borlongan are key researchers involved in this partnership.
• Cell PRAXIS BioengenhariaminorStrategic or Co-development Partner · 8 March 2011Cell PRAXIS Bioengenharia is a Brazilian platform corporation dedicated to translating research into viable therapeutic tools for regenerative medicine. The company collaborated with Cryo-Cell and USF on a published paper outlining the potential benefits of transplanting umbilical cord and menstrual blood-derived stem cells.
• Duke UniversitycoreStrategic or Co-development PartnerCryo-Cell entered into an exclusive license agreement with Duke University granting rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke. The company also holds a patent option agreement with Duke effective June 9, 2020, for Dr. Joanne Kurtzberg's patents. Duke University researchers including Dr. Joanne Kurtzberg are conducting clinical trials using cord blood for conditions such as autism and cerebral palsy.
• Saneron CCEL Therapeutics, Inc.coreStrategic or Co-development PartnerSaneron CCEL Therapeutics is a biotechnology R&D company and Cryo-Cell affiliate focused on neurological and cardiac cell therapy. Saneron holds patented and patent-pending technology relating to umbilical cord blood and Sertoli cells, developed in partnership with USF. The company is located at the Tampa Bay Technology Incubator and is committed to providing readily available, non-controversial stem cells for cellular therapies.

Scale indicators7 records

Recent moves9 records

Expansion highlights4 records

Broad incumbents

• Cryoport: Specialized cryogenic logistics and cold-chain provider for life sciences, including cell and gene therapies. Comparable to Cryo-Cell's cryopreservation infrastructure capability though operating upstream as a logistics vendor rather than a consumer cord blood bank.
• Chart Industries (Cryogenic Technologies): Industrial cryogenic equipment manufacturer (including MVE biological storage and BioMed services) supplying LN2 storage and handling infrastructure used by biobanks and cell therapy companies. Adjacent infrastructure peer to Cryo-Cell's storage operations.

Direct peers

• Americord Registry: U.S.-based private cord blood, cord tissue, and placental tissue bank targeting the same expectant-parent segment. Competes directly with Cryo-Cell on price, processing technology, and bundle offerings.
• StemCyte: Hybrid public/private cord blood bank with operations in the U.S. and internationally. Overlaps with Cryo-Cell on private family banking and uses similar FDA, AABB, and FACT accreditation frameworks.
• Cord Blood Registry (CBR): One of the largest U.S. private cord blood banks (operated by CooperCompanies), offering umbilical cord blood and cord tissue storage to expectant parents. Direct competitor to Cryo-Cell in the same consumer-driven private banking category with similar accreditation and physician-referral channels.
• LifebankUSA (Cell Care Therapeutics): Canadian-based private cord blood, cord tissue, and placental stem cell bank serving North American families. A direct competitor to Cryo-Cell with similar consumer marketing and recurring storage revenue model.
• ViaCord: Long-standing U.S. private cord blood and cord tissue bank owned by Revvity (formerly PerkinElmer). Competes head-to-head with Cryo-Cell on expectant-parent enrollment, processing technology differentiation, and recurring storage revenue.

Emerging players

• Cesca Therapeutics (now part of Restem): Cell therapy company historically focused on autologous cord blood-derived treatments, particularly for hematologic and autoimmune indications. Adjacent cell therapy peer reflecting the regenerative-medicine vertical Cryo-Cell aims to monetize through its Duke and Saneron relationships.
• BioLife Solutions: Supplier of biopreservation media, cryopreservation equipment, and cold-chain consumables used by cell and gene therapy developers and biobanks. An enabling/adjacent player to Cryo-Cell's cryopreservation operations rather than a direct consumer competitor.

Regional players

• CryoHoldco / Cord Blood Banking Industry Peers: Cluster of smaller U.S. and European private cord blood banks competing in regional and price-sensitive segments. Comparable in core service but typically smaller scale and weaker accreditation stack than Cryo-Cell.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/CryoCell
• Facebookfacebook.com/stemcellbanking
• LinkedInlinkedin.com/company/cryo-cell

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cryo-Cell International